proteasome inhibitor

systematic review meta-analysis network meta-analysis

Select multiple myeloma All type of patient       carfilzomib      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	death (overall survival) (3)progression or death (progression free survival PFS) (2) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)	progression or death (progression free survival PFS)
multiple myeloma
carfilzomib
ENDEAVOR, 2016          NCT	carfilzomib	bortezomib	relapsed MM		Risk of bias	suggesting
ECOG-ACRIN    NCT	carfilzomib	bortezomid				-
CLARION    NCT	carfilzomib	bortezomid				-
ASPIRE, 2014            NCT	carfilzomib lenalidomide dexamethasone	lenalidomide and dexamethasone alone	relapsed MM		Risk of bias	suggesting
FOCUS, 2017        NCT	carfilzomib	low-dose corticosteroids	relapsed and refractory multiple myeloma (RRMM)		Risk of bias	negative